560 related articles for article (PubMed ID: 28164651)
1. Anti-Desmoglein 1 and 3 Autoantibody Levels in Endemic Pemphigus Foliaceus and Pemphigus Vulgaris from Brazil.
Oliveira LA; Marquart-Filho A; Trevilato G; Timoteo RP; Mukai M; Roselino AM; Petzl-Erler ML
Clin Lab; 2016 Jul; 62(7):1209-1216. PubMed ID: 28164651
[TBL] [Abstract][Full Text] [Related]
2. The use of BIOCHIP technique in diagnosis of different types of pemphigus: Vulgaris and foliaceus.
Adaszewska A; Kalinska-Bienias A; Jagielski P; Wozniak K; Kowalewski C
J Immunol Methods; 2019 May; 468():35-39. PubMed ID: 30910537
[TBL] [Abstract][Full Text] [Related]
3. [Detection of serum desmoglein antibody level using enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with pemphigus vulgaris].
Zhong S; Qiu YF; Han BB; Zhao JY; Zhu XJ; Chen XX
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 43(3):414-5. PubMed ID: 21681274
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to the amino-terminal domain of desmoglein 1 are retained during transition from pemphigus vulgaris to pemphigus foliaceus.
España A; Koga H; Suárez-Fernández R; Ohata C; Ishii N; Irarrazaval I; Teye K; Ohyama B; Hashimoto T
Eur J Dermatol; 2014; 24(2):174-9. PubMed ID: 24776707
[TBL] [Abstract][Full Text] [Related]
5. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of anti-desmoglein-3 antibodies in endemic regions of Fogo selvagem in Brazil.
Hilario-Vargas J; Dasher DA; Li N; Aoki V; Hans-Filho G; dos Santos V; Qaqish BF; Rivitti EA; Diaz LA;
J Invest Dermatol; 2006 Sep; 126(9):2044-8. PubMed ID: 16763546
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin autoantibody profile in patients with pemphigus vulgaris.
Oliveira ME; Culton DA; Prisayanh P; Qaqish BF; Diaz LA
Br J Dermatol; 2013 Oct; 169(4):812-8. PubMed ID: 23725016
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of sensitivity and specificity of enzyme-linked immunosorbent assay (ELISA) for detecting antidesmoglein 1 and 3 in Thai patients with pemphigus vulgaris and foliaceus.
Kulkollakarn S; Wattanakrai P; Vachiramon V; Chalidapongse P
J Med Assoc Thai; 2008 Nov; 91(11):1663-8. PubMed ID: 19127786
[TBL] [Abstract][Full Text] [Related]
9. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
[TBL] [Abstract][Full Text] [Related]
10. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.
Amagai M; Tsunoda K; Zillikens D; Nagai T; Nishikawa T
J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):167-70. PubMed ID: 10025740
[TBL] [Abstract][Full Text] [Related]
11. Salivary Samples for the Diagnosis of Pemphigus vulgaris Using the BIOCHIP Approach: a Pilot Study.
Russo I; Saponeri A; Michelotto A; Alaibac M
In Vivo; 2017 Jan; 31(1):97-99. PubMed ID: 28064226
[TBL] [Abstract][Full Text] [Related]
12. The mapping of linear B-cell epitope regions in the extracellular parts of the desmoglein 1 and 3 proteins: recognition of immobilized peptides by pemphigus patients' serum autoantibodies.
Szabados H; Bősze S; Silló P; Kárpáti S; Hudecz F; Uray K
J Pept Sci; 2013 Feb; 19(2):84-94. PubMed ID: 23297065
[TBL] [Abstract][Full Text] [Related]
13. Using desmoglein 1 and 3 enzyme-linked immunosorbent assay as an adjunct diagnostic tool for pemphigus.
Huang CH; Chen CC; Wang CJ; Chang YT; Liu HN
J Chin Med Assoc; 2007 Feb; 70(2):65-70. PubMed ID: 17339147
[TBL] [Abstract][Full Text] [Related]
14. Epitope analysis of antidesmoglein 1 autoantibodies from patients with pemphigus foliaceus across different activity stages.
Kamiya K; Aoyama Y; Yamasaki O; Kamata A; Yamagami J; Iwatsuki K; Tokura Y
Br J Dermatol; 2016 Jan; 174(1):113-9. PubMed ID: 26294113
[TBL] [Abstract][Full Text] [Related]
15. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
Atzori L; Deidda S; Aste N
G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of specific anti-desmoglein 1 and 3 enzyme-linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity.
Barnadas MA; Rubiales MV; Gich I; Gelpí C
Int J Dermatol; 2015 Nov; 54(11):1261-8. PubMed ID: 25754029
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Tracking of Autoantibody Levels in a Pemphigus Vulgaris Patient: Support for a Role of Anti-Desmoglein 1 Autoantibodies as Predictors of Disease Progression.
Abidi NY; Lainiotis I; Malikowski G; Seiffert-Sinha K; Sinha AA
J Drugs Dermatol; 2017 Feb; 16(2):135-139. PubMed ID: 28300855
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin is an additional immunological target for pemphigus autoantibodies.
Evangelista F; Dasher DA; Diaz LA; Prisayanh PS; Li N
J Invest Dermatol; 2008 Jul; 128(7):1710-8. PubMed ID: 18219275
[TBL] [Abstract][Full Text] [Related]
19. Five Japanese cases of antidesmoglein 1 antibody-positive and antidesmoglein 3 antibody-negative pemphigus with oral lesions.
Koga H; Ohyama B; Tsuruta D; Ishii N; Hamada T; Dainichi T; Natsuaki Y; Sogame R; Fukuda S; Karashima T; Tada J; Yamashiro M; Uezato H; Chan PT; Hashimoto T
Br J Dermatol; 2012 May; 166(5):976-80. PubMed ID: 22242828
[TBL] [Abstract][Full Text] [Related]
20. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels.
Harman KE; Seed PT; Gratian MJ; Bhogal BS; Challacombe SJ; Black MM
Br J Dermatol; 2001 Apr; 144(4):775-80. PubMed ID: 11298536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
